/HUGE
HUGE Stock - FSD Pharma Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.09-10.10%
$0.01 (-10.10%) • Aug 14
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.86
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HUGE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.09 – $0.09
TARGET (TP)$0.10
STOP LOSS$0.08
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.85
52W High$109.19
52W Low$0.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $196,819 |
| Gross Profit | $-2,552,278 | $-4,357,630 | $-4,009,926 | $-4,106,506 | $-1,842,651 |
| Gross Margin | N/A | N/A | N/A | N/A | -936.2% |
| Operating Income | $-19,929,008 | $-27,429,611 | $-33,743,660 | $-30,691,088 | $-28,072,294.395 |
| Net Income | $-18,564,915 | $-23,322,074 | $-35,405,917 | $-32,719,229 | $-40,053,255.453 |
| Net Margin | N/A | N/A | N/A | N/A | -20350.3% |
| EPS | $-0.47 | $-0.60 | $-1.01 | $-2.72 | $-5.68 |
Company Overview
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HUGEBeat Rate
50%
Last 6 quarters
Avg Surprise
+28.6%
EPS vs Estimate
Beats / Misses
3/2
1 met exactly
Latest EPS
$-0.08
Q3 2024
EPS Surprise History
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
+78.6%
$-0.03vs$-0.14
Q1 24
+71.4%
$-0.04vs$-0.14
Q2 24
0.0%
$-0.05vs$-0.05
Q3 24
-33.3%
$-0.08vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 12, 2025 | — | — | — | — |
Q2 2025 | May 12, 2025 | — | — | — | — |
Q1 2025 | Mar 26, 2025 | — | — | — | — |
Q4 2024 | Nov 12, 2024 | $-0.06 | — | — | — |
Q3 2024 | Aug 14, 2024 | $-0.06 | $-0.08 | -33.3% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.05 | $-0.05 | 0.0% | = MET |
Q1 2024 | Mar 28, 2024 | $-0.14 | $-0.04 | +71.4% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.14 | $-0.03 | +78.6% | ✓ BEAT |
Q3 2023 | Jul 20, 2023 | — | $-0.14 | — | — |
Q2 2023 | May 12, 2023 | — | $-0.26 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.16 | — | — |
Q4 2022 | Nov 11, 2022 | — | $-0.19 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-0.21 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.14 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.14 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.15 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-0.35 | — | — |
Q2 2021 | May 7, 2021 | — | $-0.35 | — | — |
Q1 2021 | Mar 16, 2021 | $-1.40 | $-0.22 | +84.3% | ✓ BEAT |
Q4 2020 | Nov 12, 2020 | $-0.55 | $-0.71 | -29.1% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about HUGE
What is HUGE's current stock price?
FSD Pharma Inc. (HUGE) is currently trading at $0.09 per share. The stock has moved -10.10% today.
What is the analyst price target for HUGE?
No analyst price targets are currently available for this stock.
What sector is FSD Pharma Inc. in?
FSD Pharma Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is HUGE's market cap?
FSD Pharma Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does HUGE pay dividends?
No, FSD Pharma Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACOR
Acorda Therapeutics, Inc.
$0.66
Mkt Cap: $0.0B
BFRI
Biofrontera Inc.
$0.77
Mkt Cap: $0.0B
BHHKF
Craftport Cannabis Corp.
$0.00
Mkt Cap: $0.0B
CNNA
Cann American Corp.
$0.00
Mkt Cap: $0.0B
CVGRF
City View Green Holdings Inc.
$0.05
Mkt Cap: $0.0B
ERBB
American Green, Inc.
$0.00
Mkt Cap: $0.0B
GBHPF
Global Hemp Group Inc.
$0.01
Mkt Cap: $0.0B
GCAN
The Greater Cannabis Company, Inc.
$0.08
Mkt Cap: $0.0B
GRCU
Green Cures & Botanical Distribution Inc.
$0.00
Mkt Cap: $0.0B
GXXY
Galexxy Holdings, Inc.
$0.01
Mkt Cap: $0.0B
Explore stocks similar to HUGE for comparison